VN Research & Consulting
 Like us on facebook  Follow us on twitter  Follow us on LinkedIn  IndiaNotes on Google Plus  IndiaNotes on Pinterest  IndiaNotes on Stumbleupon  Subscribe to our feeds

Stocks  A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
You are here: IndiaNotes

Filter search : Quote Research All

Reports for search string : new launches

Buy Torrent Pharma for an upside potential of 19%
Envisaging a healthy growth in India and Brazil business led by new launches and improvement in sales force productivity, we initiate coverage on the stock with BUY recommendation and Target Price....
Reliance Securities, 15 Sep 2017
Tata Motors: Q1FY18 hit by forex and other costs; LKP Securities prune down target price
According to LKP Research, TAMO reported weak set of numbers in Q1, which also happens to be the seasonally weakest quarter for the company. On weak Q1, they are pruning down our estimates and target ...
LKP Securities, 11 Aug 2017
Zee Entertainment Q1FY18: LKP Securities downgrade the stock to 'neutral'
Due to higher investments and higher tax outgo hereon, LKP Securities have downgraded the stock to NEUTRAL from BUY on rich valuations. They have also slightly reduced their bottomline estimates for F...
LKP Securities, 26 Jul 2017
Ashok Leyland Q1FY18: LKP Securities downgrade to 'Neutral'
According to LKP Securities, in view of disappointing Q1, the margin estimates for FY18/19E have been reduced and the target price has also been cut down. They are also therefore downgrading the stock...
LKP Securities, 25 Jul 2017
Ashok Leyland Q4FY17: Macro improvement may drive the performance; Buy
According to LKP Securities, once the GST and BS IV transition gets behind the company, a sustained growth in the MHCV cycle on the back of strong macro cues is expected to continue at ~10% thereon. T...
LKP Securities, 29 May 2017
Tata Motors Q4FY17: Good recovery on the way; LKP Securities upgrade from 'neutral' to 'buy'
According to LKP Securities, Tata Motors reported robust set of numbers in Q4, which also happens to be the seasonally strongest quarter for the company. They are thereby upgrading the stock from Neut...
LKP Securities, 25 May 2017
Zee Entertainment Q4FY17: Decent set of numbers in difficult times; Buy
According to LKP Securities, Zee Entertainment seems moving ahead as per expectations. However, due to higher investments, we have slightly reduced their bottomline estimates for FY18E and FY19E to d...
LKP Securities, 11 May 2017
HUDCO IPO: Investors with long term horizon may consider for investment
The Company is set to play a significant role in PMAY under Housing for All (HFA) by 2022 and thus the outlook of the company looks bright. Moreover, it enjoys AAA rating for its debt plans from ratin...
SMC, 08 May 2017
Alembic Pharma Q4FY17: Book partial profits and 'hold' on the remaining stock
Nirmal Bang believe that the company has successfully crafted a niche for itself in US markets and likely to remain a focus player. They recommend investors to book partial profits and HOLD on the rem...
Nirmal Bang, 05 May 2017
Q3FY17 Results: Top picks in the AUTO sector
Auto companies registered stressed performance in sales volumes during Q3FY17. Except for Eicherís Royal Enfield, Tataís Tiago and few models of Maruti (Breeza, S‐Cross & Baleno)which have long ...
IndiaNivesh, 28 Feb 2017
Tata Motors: Re-rating likely due to strong volume growth followed by gradual margin recovery
According to Way2wealth, Tata Motors' current stock price factors most of the negatives and concern about the company. We believe strong volume growth followed by gradual margin recovery could rerate ...
Way2wealth, 16 Feb 2017
Lupin Q3FY17: Prabhudas Lilladher maintain 'accumulate' with increased target
Prabhudas Lilladher are rolling over earnings estimates to FY19E and increasing their 12 months target price from the previous of Rs 1,650. The new target is based on PER of 22.4x Sep 18 earnings. The...
Prabhudas Lilladher, 10 Feb 2017
What Does Realty Sector Expect From The Union Budget 2017?
The realty sector hopes that the Union Budget for 2017-2018 which comes just a few months after demonetisation plus a lacklustre year shall help realty recovery
Dynamic Equities Pvt Ltd, 23 Jan 2017
Aurobindo Pharma: Valuation gap will narrow going forward
Way2wealth believe the valuation gap will narrow going forward on the back of the company's strong US portfolio, synergies from recent acquisition & improving earnings visibility. At its CMP of 704.55...
Way2wealth, 12 Jan 2017
After a Bumpy 2016, Realty heads towards Consolidation
Real estate sector has faced chaotic times in 2016 and is staring at another challenging year ahead, following disturbance caused by reforms like the Real Estate Regulation Act (RERA) and Demonetizati...
Dynamic Equities Pvt Ltd, 05 Jan 2017
Rudra Shares recommend a leading dairy farm scrip for a 1-year target of Rs 342
According to Rudra Shares, the Company expects a good amount of business coming from Cheese as it expand the capacity of cheese plant from 40 MT to 60 MT by FY17. It's aim to increase market share & d...
Rudra Shares and Stock Brokers, 04 Jan 2017
Lumax Industries: CD Equisearch revise rating to 'Accumulate' and raise price target
According to CD Equisearch, uncertainty in the economy is likely to cloud the potential of the company in the near term and so they are revising their rating on the stock to 'accumulate' with a target...
CD Equisearch Pvt Ltd, 22 Dec 2016
Fundamental picks: These stocks have an upside of 23% & 22% respectively
SMC are recommending Power Grid Corporation and LG Balakrishnan & Bros on fundamental grounds for a tenure of 8-10 months. They are also sharing with us the targets for both the scrips, which imply an...
SMC, 21 Dec 2016
Bata India: Motilal Oswal upgrade to 'buy' with target implying 16% upside
Factoring in the impact of demonetization, Motilal Oswal are cutting revenue estimates by 10%/6% and PAT estimates by 15%/6% for FY17/FY18. They are valuing Bata at 34x (up from 30x) and upgrading the...
Motilal Oswal, 07 Dec 2016
Aurobindo Pharma Q2FY17 profit up 33.2% beating analysts' estimates
Aurobindo Pharma Ltd, fiscal second-quarter profit rose 33.2%, beating analystsí estimates, on higher sales of generic drugs in the US. The Sales grew by sharp 51% YoY to Rs 2881.22 crore.
SMC, 18 Nov 2016
View All

Intraday Tips

What are technical calls?

View Stock Advice by: